Neuraminidase-supplemented compositions

In a vaccine composition which comprises an anti-influenza vaccine, wherein the improvement comprises having as an additive:

• substantially pure, influenza neuraminidase and
• wherein influenza hemagglutinin protein is also present in the composition, and the neuraminidase protein is present in a molar ratio of from about 0.05 to about 0.15 relative to the hemagglutinin protein.

In a vaccine composition which comprises an anti-influenza vaccine, wherein the improvement comprises having as an additive:

• substantially pure, mature, glycosylated influenza hemagglutinin protein and said protein is immunogenic;
• and,
• substantially pure, influenza neuraminidase and wherein the neuraminidase protein is present in a molar ratio of from about 0.15 to 0.3 relative to the hemagglutinin protein.

In a vaccine composition which comprises an anti-influenza vaccine, wherein the improvement comprises having as an additive:

• substantially pure, mature, glycosylated influenza hemagglutinin protein and said protein is immunogenic;
• and,
• substantially pure, influenza neuraminidase protein and wherein the neuraminidase protein is present in a molar ratio of from about 0.05 to 0.15 relative to the hemagglutinin protein.

In a vaccine composition which comprises an anti-influenza vaccine, wherein the improvement comprises having as an additive:

• substantially pure, influenza neuraminidase protein and
• wherein influenza hemagglutinin protein is also present in the composition, and the total neuraminidase protein is present in a molar ratio of from about 0.15 to 0.3 relative to the total hemagglutinin protein.

In a vaccine composition which comprises an anti-influenza vaccine, wherein the improvement comprises having as an additive:

• substantially pure, influenza neuraminidase and
• wherein influenza hemagglutinin protein is also present in the composition, and the total neuraminidase protein is present in a molar ratio of from about 0.05 to about 0.15 relative to the total hemagglutinin protein.

In a vaccine composition which comprises an anti-influenza vaccine, wherein the improvement comprises having as an additive:

• substantially pure, mature, glycosylated influenza hemagglutinin protein and said protein is immunogenic;
• and,
• substantially pure, influenza neuraminidase and wherein the total neuraminidase protein is present in a molar ratio of from about 0.15 to 0.3 relative to the total hemagglutinin protein.

In a vaccine composition which comprises an anti-influenza vaccine, wherein the improvement comprises having as an additive:

• substantially pure, mature, glycosylated influenza hemagglutinin protein and said protein is immunogenic;
• and,
• substantially pure, influenza neuraminidase protein and wherein the total neuraminidase protein is present in a molar ratio of from about 0.05 to 0.15 relative to the total the hemagglutinin protein.